Literature DB >> 582409

[Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)].

H Knauf, E Mutschler, K D Völger, U Wais.   

Abstract

Since triamterene (TA) is rapidly metabolized to hydroxytriamterene (OH-TA) and then to its sulfuric acid ester (OH-TA-ester) the question arose whether the metabolites are still effective on ion transport as is triamterene. The effect of the metabolites was studied in microperfusion experiments on the rat submaxillary duct, which resembles the distal nephron and is considered the site of action of triamterene. Added to the lumen the phase-I- as well as the phase-II-metabolites decreased reabsorption of Na+, secretion of K+, and yielded an accumulation of HCO3-. These effects of the metabolites were produced by equimolar concentrations and are almost identical to those of native triamterene. In conclusion, the phase-II-metabolite must be considered to be essentially responsible for the natriuresis and antikaliuresis observed after oral administration of triamterene.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 582409

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Dissociation of the natriuretic and antikaliuretic properties of triamterene derivatives by dose-response experiments.

Authors:  H Priewer; E Wolf; H Kraft; H Knauf; E Mutschler
Journal:  Pharm Res       Date:  1987-02       Impact factor: 4.200

2.  Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.

Authors:  D Loew; D Barkow; O Schuster; H E Knoell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].

Authors:  E Mutschler; H J Gilfrich; H Knauf; W Möhrke; K D Völger
Journal:  Klin Wochenschr       Date:  1983-09-15

4.  Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Authors:  H J Gilfrich; G Kremer; W Möhrke; E Mutschler; K D Völger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Delayed elimination of triamterene and its active metabolite in chronic renal failure.

Authors:  H Knauf; W Möhrke; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.